Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Non-injectable Insulin Market Valuation Change Between Now And 2029?

The market for non-injectable insulin has seen swift expansion in the past few years. The industry, which had a value of $1.92 billion in 2024, is projected to increase to $2.14 billion by 2025, representing a compound annual growth rate (CAGR) of 11.1%. Factors like better patient adherence to treatment, the resolution of needle-related fears, improved life quality, simpler administration methods, and steady control of blood sugar levels have contributed to this historic growth.

The market size for non-injectable insulin is set to experience robust expansion in the coming years, with predictions suggesting it will reach $3.11 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth over the forecast period can be credited to ongoing efforts in patient compliance, solutions for persistent needle fear, further life quality augmentation, continued safety upgrades, and the minimization of infection and injury risks. In the same period, key trends to watch include technological advancements, the development of techno-solutional approaches, the merging of digital health, applications of nanotechnology, and combined therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What External And Internal Drivers Are Influencing The Non-injectable Insulin Market?

The escalating issues of obesity and diabetes are anticipated to fuel the expansion of the non-injectable insulin market. Obesity, defined by an excess buildup of body fat typically resulting from an imbalance between caloric intake and energy expenditure, along with diabetes mellitus – commonly known as diabetes, a metabolic disorder group characterized by sustained high blood sugar levels, are both treated by non-injectable insulin. This form of treatment has the potential to ameliorate management by tackling impediments to insulin therapy, offering potential weight management benefits, and introducing more convenient treatment alternatives. For example, the World Heart Federation, a non-governmental organization based in Switzerland, predicts a global obesity spike in 2022, foreseeing the number of children and adults struggling with overweight and obesity rising from an estimated 2.3 billion in 2021 to 2.7 billion by 2025. In addition, a report released by the British Diabetic Association, a UK-based diabetes charity, in April 2023, indicated that in the UK, there are 4.3 million diabetes patients, and over 2.4 million individuals are at a high risk of developing type 2 diabetes. The registration figures for 2021-22 have seen an increase by 148,951 compared to the previous year. Thus, the escalating issues of obesity and diabetes are catalyzing the expansion of the non-injectable insulin market.

Which Segments Define The Structure Of The Non-injectable Insulin Market?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

What Strategic Shifts And Innovations Are Influencing The Non-injectable Insulin Market?

Key players in the non-injectable insulin market are turning their attention towards pioneering advancements in drug delivery technology like the needle-free oral insulin spray. This step is significant in enhancing the lives of those managing their diabetes through numerous insulin injections. A needle-free insulin spray offers a blood glucose regulation method that is convenient and painless, as it can directly be sprayed into one’s mouth. An example of this is when NiedlFree Technologies, a tech platform based in India, unveiled an oral insulin spray named Ozulin in November 2023. The aim of this innovation is to create a more user-friendly response for those living with diabetes. This is particularly relevant for individuals who struggle with traditional insulin injections. Upon approval, Ozulin could revolutionize the diabetic world by providing a more convenient and less painful substitute for insulin injections.

Which Firms Are Making The Biggest Impact In The Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Is Forecasted To Lead The Non-injectable Insulin Market In The Coming Years?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model